For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Nirmatrelvir with Ritonavir - Covid-19
PAD Profile : Nirmatrelvir with Ritonavir - Covid-19
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
Other Indications
No indications returned.
Additional Documents
Committee Recommendations
The Surrey Heartland Integrated Care System Area Prescribing Committee agree implementation of NICE TA878 Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19.
Nirmatrelvir with ritonavir *(Paxlovid) is agreed as RED for prescription only by the commissioned CMDU service (not for prescribing through A&E / hospital clinics)
*if a patient who falls into one of the high risk cohorts is in hospital and gets COVID-19 (not admitted due to COVID) then these individuals should be treated with Paxlovid / Sotrovimab in line with NICE TA878 whilst they are an inpatient.
Associated BNF Codes
No BNF codes returned.